ASKA Pharmaceutical HoldingsLtd Management
Management criteria checks 2/4
ASKA Pharmaceutical HoldingsLtd's CEO is Takashi Yamaguchi, appointed in Jun 1991, has a tenure of 33.92 years. directly owns 2.83% of the company’s shares, worth ¥1.88B. The average tenure of the management team and the board of directors is 7 years and 3.4 years respectively.
Key information
Takashi Yamaguchi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 33.9yrs |
| CEO ownership | 2.8% |
| Management average tenure | 7yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Weak Statutory Earnings May Not Tell The Whole Story For ASKA Pharmaceutical HoldingsLtd (TSE:4886)
May 21
ASKA Pharmaceutical HoldingsLtd (TSE:4886) Is Due To Pay A Dividend Of ¥25.00
Mar 13ASKA Pharmaceutical HoldingsLtd (TSE:4886) Has Announced A Dividend Of ¥25.00
Feb 27ASKA Pharmaceutical HoldingsLtd's (TSE:4886) Dividend Will Be ¥25.00
Feb 08ASKA Pharmaceutical HoldingsLtd's (TSE:4886) Profits May Not Reveal Underlying Issues
Nov 19ASKA Pharmaceutical HoldingsLtd's (TSE:4886) Solid Profits Have Weak Fundamentals
May 21CEO
Takashi Yamaguchi (72 yo)
Mr. Takashi Yamaguchi has been the President and Representative Director of ASKA Pharmaceutical Holdings Co.,Ltd. (formerly known as ASKA Pharmaceutical Co., Ltd.) since June 1991 and its Chairman since Ju...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & President | 33.9yrs | no data | 2.83% ¥ 1.9b | |
| Senior Managing Director & Representative Director | 13.9yrs | no data | 0.14% ¥ 96.1m | |
| Director of Finance & Accounting Dept. | less than a year | no data | no data | |
| Senior Managing Director & Representative Director | 7.9yrs | no data | 0.49% ¥ 323.3m | |
| Managing Executive Officer & Director | 6.1yrs | no data | 0.028% ¥ 18.7m | |
| Managing Executive Officer & Director | 4.9yrs | no data | 0.039% ¥ 25.8m | |
| Executive Corporate Officer & Director of Group Business Management Division | no data | no data | no data |
Experienced Management: 4886's management team is seasoned and experienced (7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & President | 33.9yrs | no data | 2.83% ¥ 1.9b | |
| Senior Managing Director & Representative Director | 13.9yrs | no data | 0.14% ¥ 96.1m | |
| Senior Managing Director & Representative Director | 7.9yrs | no data | 0.49% ¥ 323.3m | |
| Managing Executive Officer & Director | 2.9yrs | no data | 0.028% ¥ 18.7m | |
| Managing Executive Officer & Director | 2.9yrs | no data | 0.039% ¥ 25.8m | |
| Independent Outside Director | 13.9yrs | no data | no data | |
| Audit & Supervisory Board Member | 3.9yrs | no data | 0.042% ¥ 28.1m | |
| Outside Audit & Supervisory Board Member | 7.9yrs | no data | no data | |
| Independent Outside Director | 1.9yrs | no data | no data | |
| Independent Outside Director | 1.9yrs | no data | no data | |
| Audit & Supervisory Board Member | less than a year | no data | 0.025% ¥ 16.4m | |
| Independent Outside Director | less than a year | no data | no data |
Experienced Board: 4886's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 20:28 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ASKA Pharmaceutical Holdings Co.,Ltd. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Seohyun Lee | Citigroup Inc |
| Masao Yoshida | Ichiyoshi Research Institute Inc. |